½ÃÇè°ú¸ñº° °øÁö»çÇ×

  • ½ÃÇè¾È³»
  • ½ÃÇè°ú¸ñº° °øÁö»çÇ×

2025³âµµ Á¦3ȸ Àü¹®¾à»ç ÀڰݽÃÇè °øÁö»çÇ×

- ½ÉÇ÷°ü -

1½ÃÇè³»¿ë ±¸¼º ¹× ½ÃÇè½Ã°£ (Àü °ú¸ñ °øÅë»çÇ×)

1)½ÃÇè³»¿ëÀº °øÅ뿵¿ª°ú Àü¹®¿µ¿ªÀ¸·Î ±¸¼ºµÊ.

  • °øÅ뿵¿ª : ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò
  • Àü¹®¿µ¿ª : ½ÉÇ÷°ü

2)½ÃÇè½Ã°£

  • ÃÑ ½ÃÇè½Ã°£ : ½ÃÇèÁغñ ¹× ¾È³», °øÁö½Ã°£ µîÀ» Æ÷ÇÔÇÏ¿© 180ºÐ(3½Ã°£).

2ÃâÁ¦À¯Çü ¹× ¹èÁ¡

1)°øÅ뿵¿ª(ÃÑ20Á¡) : °´°ü½Ä 20¹®Ç× (°¢ 1Á¡)

2)Àü¹®¿µ¿ª(ÃÑ80Á¡) : °´°ü½Ä 80¹®Ç× (°¢ 1Á¡)

  • ¾à¹°¿ä¹ýÀÇ ÀûÀý¼º °ËÅä
  • ¾à¹°¿ä¹ý °ü·Ã ¹®Á¦(drug-related problems) ÆÄ¾Ç ¹× ÇØ°á¹æ¾È Á¦½Ã
  • ȯÀÚ ¸ÂÃãÇü ¾à¹° ¼±Åà ¹× ¾à¹°¿ä¹ý °èȹ ¼ö¸³
  • ¾à¹°¿ä¹ýÀÇ Ä¡·áÈ¿°ú ¹× ¾à¹° ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ
  • ȯÀÚ º¹¾à»ó´ã ¹× ±³À°

3ÃâÁ¦¹üÀ§

1)°øÅ뿵¿ª ÃâÁ¦¹üÀ§ : ÀǾàÅë°èÀÇ ±âº»°³³ä ¹× À̸¦ Ȱ¿ëÇÑ ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë µî¿¡ °üÇÑ ¹®Ç×À¸·Î ÀÌ·ç¾îÁü.

  • ±Ù°Å±â¹ÝÀÇÇÐ(Evidence-Based Medicine) ¹× ±Ù°Å±â¹ÝÀÓ»ó½Ç¹«(Evidence-Based Clinical Practice, EBCP)ÀÇ ÀÌÇØ
  • ÀǾ๮ÇåÀÇ Á¾·ù ¹× Ư¡
  • ÀÓ»óÅë°èÀÇ ±âº» °³³ä
  • ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë

2)Àü¹®¿µ¿ª ÃâÁ¦¹üÀ§

  • ±Þ¼º°ü»óµ¿¸ÆÁõÈıº
  • ¾ÈÁ¤ÇãÇ÷½ÉÀ庴(Çù½ÉÁõ)
  • °íÇ÷¾Ð
  • ÀÌ»óÁöÁúÇ÷Áõ
  • ½ÉºÎÀü
  • ºÎÁ¤¸Æ(½É¹æ¼¼µ¿)
  • ³úÁ¹Áß
  • Á¤¸ÆÇ÷Àü»öÀüÁõ

4Âü°í¹®Çå

1)Àü °ú¸ñ °øÅë Âü°í¹®Çå

°¡)¾à¹°Ä¡·áÇÐ °ü·Ã Âü°í¹®Çå

  • DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 12th ed., 2023.
  • Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 12th ed., 2023.
  • Zeind CS, Carvalho MG, Cheng JW, Zaiken K, LaPointe T, eds. Applied Therapeutics: The Clinical Use of Drugs. 12th ed., 2023.
  • Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver PB, Lee KC. Pharmacotherapy Principles & Practice. 6th ed., 2022.
  • Çѱ¹ÀÓ»ó¾àÇÐȸ. ¾à¹°Ä¡·áÇÐ Á¦6°³Á¤. ½ÅÀϺϽº. 2025

³ª)°øÅ뿵¿ª(ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò) °ü·Ã Âü°í¹®Çå

  • ¾à±¹½Ç¹«ºÐ°úȸ, ¾à·áÁ¤º¸ÇÐ, ½ÅÀϺϽº, 2021³â, Section III, Á¦ 9-13Àå, 16Àå
  • ¾à±¹½Ç¹«ºÐ°úȸ, ÀÓ»ó½Ç¹«¾àÇÐ, ½ÅÀϺϽº, 2024³â, 27Àå, 29Àå
  • Guyatt G, Rennie D, Meade MO & Cook DJ. Users¡¯ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed., New York, USA: McGraw Hill Education & The JAMA Network. 2015.
  • DiCenzo R, ed. Clinical Pharmacist's Guide to Biostatistics and Literature Evaluation. 2nd ed., Lenexa, KS, USA: American College of Clinical Pharmacy. 2015.
  • Browner WS, Thomas B Newman TB, Cummings SR. Designing Clinical Research. 5th ed. Wolters Kluwer. 2022.
  • Malone PM, Witt BA, Malone MJ, Peterson DM. Drug Information: A Guide for Pharmacists, 7th ed. McGraw Hill. 2022.
  • Canadian Medical Association Journal (CMAJ) evidence based medicine (EBM) series
    • Wyer PC, et al. Tips for learning and teaching evidence-based medicine: Introduction to the series. CMAJ 2004;171:347-8.
    • Barratt A, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.
    • Montoria VM, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2005;171:611-5.

2)Àü¹®¿µ¿ª °ü·Ã Âü°í¹®Çå

°¡)±Þ¼º°ü»óµ¿¸ÆÁõÈıº, ¾ÈÁ¤ÇãÇ÷½ÉÀ庴(Çù½ÉÁõ)

  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140
  • 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24): e139-e228
  • 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134(10):e123-155.
  • 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177
  • 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477
  • 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2021;42(14): 1289-1367
  • 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826
  • 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21-e129
  • 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Aug 29;82(9):833-955.
  • 2013 ¾ÈÁ¤Çü Çù½ÉÁõ Ç¥ÁØÁø·á ±Ç°í¾È. ´ëÇѽÉÀåÇÐȸ/ÇãÇ÷¼º ½ÉÁúȯ Àӻ󿬱¸¼¾ÅÍ
  • 2013 ±Þ¼º°üµ¿¸ÆÁõÈıº Ç¥ÁØÁø·á ±Ç°í¾È. ´ëÇѽÉÀåÇÐȸ/ÇãÇ÷¼º ½ÉÁúȯ Àӻ󿬱¸¼¾ÅÍ
  • 2020 ±Þ¼º½É±Ù°æ»öÁõÀÇ ¾à¹°Ä¡·á¿¡ ´ëÇÑ Àü¹®°¡ ÇÕÀǹ®. ´ëÇѽÉÀåÇÐȸ
  • 2021 ±Þ¼º½É±Ù°æ»öÁõÀÇ Àç°³Åë¼ú¿¡ ´ëÇÑ Àü¹®°¡ ÇÕÀǹ®. ´ëÇѽÉÀåÇÐȸ
  • 2021 ¼ö¼ú ¹× ½Ã¼ú ½Ã Ç×Ç÷ÀüÁ¦ »ç¿ë¿¡ ´ëÇÑ Àü¹®°¡ ÇÕÀǹ®. ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ

³ª)°íÇ÷¾Ð

  • 2014 evidence-based guideline for the management of high blood pressure in adults - report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 2014;311(5):507-20.
  • 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248
  • 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071.
  • Hypertension in adults: diagnosis and management. NICE guideline (NG136). 28 August 2019; 1-52 Last updated: 21 November 2023 [Internet: nice.org.uk/guidance/ng136 ] (NICE; National Institute for Health and Care Excellence)
  • 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO) Eur Heart J. 2024; 45(38): 3912-4018
  • 2019 ÀÏÂ÷ ÀÇ·á¿ë ±Ù°Å±â¹Ý °íÇ÷¾Ð ÀÓ»óÁø·áÁöħ. ´ëÇÑÀÇÇÐȸ, Áúº´°ü¸®Ã».
  • 2022³â °íÇ÷¾Ð Áø·áÁöħ. ´ëÇѰíÇ÷¾ÐÇÐȸ

´Ù)ÀÌ»óÁöÁúÇ÷Áõ

  • American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/SPC/NLA/PCNA guideline on the management of blood cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1182-e1186
  • 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188
  • 2018 ÀÏÂ÷ ÀÇ·á¿ë ±Ù°Å±â¹Ý ÀÌ»óÁöÁúÇ÷Áõ ±Ç°í ¿ä¾àº». ´ëÇÑÀÇÇÐȸ
  • 2022 ÀÌ»óÁöÁúÇ÷Áõ Áø·áÁöħ. Á¦5ÆÇ Çѱ¹ÁöÁú¡¤µ¿¸Æ°æÈ­ÇÐȸ Áø·áÁöħÀ§¿øÈ¸

¶ó) ½ÉºÎÀü

  • 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599-3726
  • 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032
  • 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639
  • 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835-1878
  • 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-1488
  • 2022 ½ÉºÎÀü Áø·áÁöħ. ´ëÇѽɺÎÀüÇÐȸ

¸¶) ºÎÁ¤¸Æ(½É¹æ¼¼µ¿)

  • Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-e575S
  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-2104
  • 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2016;37:2893-2962
  • Antithrombotic therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-1201
  • 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. J Am Coll Cardiol. 2019;74:104-132
  • 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-toracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498
  • 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676
  • 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156
  • 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676
  • 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156
  • 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414
  • 2018 ´ëÇѺÎÁ¤¸ÆÇÐȸ ºñÆÇ¸·¼º ½É¹æ¼¼µ¿ ȯÀÚÀÇ ³úÁ¹Áß ¿¹¹æÁöħ. Korean J Med. 2018;93(2):87-109
  • 2021 ´ëÇѺÎÁ¤¸ÆÇÐȸ ½É¹æ¼¼µ¿ ȯÀÚÀÇ ³úÁ¹Áß ¿¹¹æ °ü¸® Áöħ. Korean J Med 2021;96(4):296-311
  • ½É¹æ¼¼µ¿ Áø·áÁöħ. ´ëÇѺÎÁ¤¸ÆÇÐȸ. 2021
  • 2022 ´ëÇѺÎÁ¤¸ÆÇÐȸ ½É¹æ¼¼µ¿ ȯÀÚ¿¡¼­ ºñŸ¹ÎK ºñÀÇÁ¸¼º °æ±¸¿ë Ç×ÀÀ°íÁ¦(NOAC) »ç¿ë Áöħ. ½É¹æ¼¼µ¿ Áø·á Áöħ °³¹ßÀ§¿øÈ¸. 2022
  • 2024 ´ëÇѺÎÁ¤¸ÆÇÐȸ ºÎÁ¤¸Æ Áø·áÁöħ (¥°) - ½É¹æ¼¼µ¿ ÀÏ¹Ý Ä¡·á Áø·áÁöħ. ´ëÇѺÎÁ¤¸ÆÇÐȸ. 2024
  • 2024 ´ëÇѺÎÁ¤¸ÆÇÐȸ ºÎÁ¤¸Æ Áø·áÁöħ (¥°) - ½É¹æ¼¼µ¿ NOAC Ä¡·á Áø·áÁöħ. ´ëÇѺÎÁ¤¸ÆÇÐȸ. 2024

¹Ù) ³úÁ¹Áß

  • 2018 Guidelines for the early management of patients with acute ischemic stroke A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110
  • Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. Stroke. 2019;50:e344-e418
  • 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke 2024; 55(12) e344-424
  • 2022 update of the Korean clinical practice guidelines for stroke: Antithrombotic therapy for patients with acute ischemic stroke or transient ischemic attack. J Stroke. 2022;24(1):166-175
  • ³úÁ¹Áß Áø·áÁöħ(¿ä¾àº»). ´ëÇѳúÁ¹ÁßÇÐȸ. 2022

»ç) Á¤¸ÆÇ÷Àü»öÀüÁõ

  • Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):7S-47S.
  • Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352
  • 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ESC), Eur Heart J. 2020;41:543-603
  • Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545-e608
  • American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738
  • American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-3291
  • American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738
  • Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021. Chest. 2024;166(2):388-404